Invivyd (IVVD) AI Stock Analysis

• Market Cap: $84.95M
• Dividend Yield: N/A
• Average Volume (3M): 691.32K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.02
• Revenue Growth: 1941.08%
• EPS Growth: 48.93%
• Country: US
• Employees: 99
• Sector: Healthcare
• Sector Strength: 50
• Industry: Biotechnology
• EPS (TTM): -0.12
• Shares Outstanding: 120,142,815
• 10 Day Avg. Volume: 711,990
• 30 Day Avg. Volume: 691,319
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.63
• Enterprise Value/Revenue: 1.47
• Enterprise Value/Gross Profit: 1.57
• Enterprise Value/Ebitda: -0.37
• 1Y Price Target: $5.00
• Price Target Upside: 762.07% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 44 Neutral
• Price Target: ―

Invivyd's overall stock score reflects significant financial and technical weaknesses, marked by ongoing losses and bearish trends. While recent corporate developments offer a glimpse of potential strategic improvement, these are overshadowed by the current financial instability and weak market sentiment.

Positive Factors

Clinical Trials

The FDA has agreed that a single, randomized Phase 2/3 prevention trial could form the basis for a VYD2311 Biologics License Application in individuals ≥12 years and ≥40 kg, including immunocompromised patients.

Market Adoption

Inclusion in Infectious Diseases Society of America and National Comprehensive Cancer Network guidelines has expanded PEMGARDA’s relevance, particularly in B-cell lymphoma patients.

Negative Factors

Initial Launch Performance

The initial launch trajectory of PEMGARDA fell short of expectations, leading to a lowered price target.

Regulatory Challenges

The FDA has rejected Invivyd’s submission to expand PEMGARDA's Emergency Use Authorization to include COVID-19 treatment.

Invivyd Business Overview & Revenue Model

Company Description

Invivyd, Inc. (IVVD) is a biotechnology company that focuses on the discovery, development, and commercialization of innovative therapies for infectious diseases. The company's core products include monoclonal antibodies designed to treat and prevent viral infections, with a particular emphasis on addressing unmet medical needs in the field of infectious disease prevention and treatment.

How the Company Makes Money

Invivyd generates revenue primarily through the development and commercialization of its therapeutic products. The company invests in research and development to create proprietary monoclonal antibodies that can be licensed or sold to healthcare providers, pharmaceutical companies, or directly to the market. Revenue streams may include product sales, licensing agreements, and potential partnerships or collaborations with other pharmaceutical companies. These partnerships can involve co-development or co-marketing arrangements, which can significantly contribute to the company's earnings by leveraging shared resources and expertise.

Invivyd Financial Statement Overview

Summary

Invivyd faces substantial financial challenges with significant losses and negative cash flows, despite recent revenue generation. While the balance sheet shows low leverage and strong cash reserves, consistent operational losses and cash flow inefficiencies pose considerable risks. Strategic improvements are critical for future stability.

Income Statement

Invivyd's financial performance shows a challenging trajectory. The company recorded its first revenue of $25.38 million in 2024 after having no revenue in previous years, indicating a significant growth. However, the company still faces substantial net losses, with a negative net profit margin due to high operational costs. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.

Balance Sheet

Invivyd maintains a relatively strong equity position with a moderate debt load, as evidenced by a low debt-to-equity ratio. However, there has been a significant decrease in stockholders' equity over the years, and the equity ratio has declined, indicating potential risks if losses continue. The company's high cash reserves provide some financial stability.

Cash Flow

The company's cash flow situation is strained, with consistently negative free cash flow due to high operational cash outflows. The free cash flow to net income ratio remains unfavorable, indicating that the company is not generating cash from its operations. However, there is a positive trend in financing activities which have supported cash reserves.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	25.38M	0.00	0.00	0.00	0.00
Gross Profit	23.77M	-2.03M	-462.00K	-1.00K	0.00
EBITDA	-173.76M	-196.62M	-248.03M	-226.79M	-65.33M
Net Income	-169.93M	-198.64M	-234.60M	-234.29M	-65.32M
Balance Sheet
Total Assets	129.51M	229.18M	383.17M	620.09M	117.38M
Cash, Cash Equivalents and Short-Term Investments	69.35M	200.64M	371.99M	591.42M	114.99M
Total Debt	1.30M	2.17M	3.72M	0.00	0.00
Total Liabilities	61.98M	51.71M	27.20M	62.07M	182.63M
Stockholders Equity	67.54M	177.47M	355.97M	558.02M	-65.25M
Cash Flow
Free Cash Flow	-170.63M	-173.78M	-221.69M	-184.82M	-14.57M
Operating Cash Flow	-170.49M	-173.16M	-219.99M	-184.74M	-14.57M
Investing Cash Flow	-140.00K	280.68M	-230.67M	-50.71M	0.00
Financing Cash Flow	39.33M	1.04M	506.00K	662.68M	129.56M

Invivyd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.58
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IVVD, the sentiment is Negative. The current price of 0.58 is below the 20-day moving average (MA) of 0.75, below the 50-day MA of 0.75, and below the 200-day MA of 0.77, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 32.32 is Neutral, neither overbought nor oversold. The STOCH value of 10.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IVVD.

Invivyd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VTGN	59 Neutral	$101.55M	―	-46.28%	―	-33.00%	54.91%
Sector *	51 Neutral	$7.71B	-0.22	-44.71%	2.25%	22.42%	-0.92%
IVVD	44 Neutral	$84.95M	―	-120.08%	―	1941.08%	48.93%
CLSD	39 Underperform	$33.44M	―	91.63%	―	-44.63%	26.80%
VTVT	38 Underperform	$49.32M	―	-203.31%	―	-98.30%	54.90%
INZY	37 Underperform		―		―	―	-17.06%
JSPR	35 Underperform	$50.55M	―	-146.87%	―	―	-17.96%

Invivyd Corporate Events

Invivyd Secures $30 Million Loan from SVB

On April 18, 2025, Invivyd, Inc. entered into a $30 million loan agreement with Silicon Valley Bank, allowing for future capital drawdowns contingent on meeting specific conditions and milestones. This non-dilutive financing supports Invivyd’s strategic focus on enhancing per-share value and advancing its pipeline, including the monoclonal antibody candidate VYD2311, which is being developed for COVID-19 treatment and prevention.

Spark’s Take on IVVD Stock

According to Spark, TipRanks’ AI Analyst, IVVD is a Neutral.

Invivyd’s stock is under pressure due to significant financial difficulties, with ongoing losses and cash flow issues. The technical indicators suggest a bearish trend, and the valuation metrics highlight market concerns about future profitability. However, the appointment of Ajay Royan to the board is a positive corporate development that could improve strategic outcomes. Overall, the stock scores low due to financial and technical weaknesses, partially offset by potential strategic improvements.

To see Spark’s full report on IVVD stock, click here.

Invivyd Appoints Ajay Royan to Board of Directors

On March 22, 2025, Invivyd, Inc. appointed Ajay Royan, founder of Mithril Capital, to its Board of Directors, with his term expiring at the 2025 annual meeting of stockholders. Royan, a venture capitalist with a focus on healthcare, technology, and energy, will receive compensation consistent with other non-employee directors and was granted an option to acquire 100,000 shares of common stock. His appointment is expected to enhance Invivyd’s efforts to advance its monoclonal antibody technology platform, which aims to provide high-quality medicines for vulnerable populations affected by COVID-19 and other diseases.